Basel, 2019-01-29 - Unites States Patent and Trademark Office grants US patent on NBE's linker-toxin technology

NBE-Therapeutics has obtained grant of a US patent for its novel anthracycline-based ADC platform that can be used to generate highly potent and immune-stimulatory antibody drug conjugates (iADCs)

Read more

Basel, 2018-11-15 - Dr. Anthony Tolcher joins the Scientific Advisory Board of NBE-Therapeutics

Internationally renowned key opinion leader in the field of clinical development of ADCs and Board-certified Medical Oncologist, Dr. Anthony Tolcher joins the Scientific Advisory Board of NBE-Therapeutics

Read more

Basel, 2018-06-28 - Novo Holdings A/S invests CHF 20 million in a seriesB extension financing of NBE-Therapeutics

NBE-Therapeutics has closed a CHF 20 million series B extension financing round bringing the total seriesB funding of NBE to CHF 40 million

Read more

Basel, 2018-03-05 - USPTO grants US patent for NBE-Therapeutics' core conjugation technology

NBE-Therapeutics has obtained a granted patent for the company's core SMAC-Technology in the United States

Read more

Basel, 2017-11-28 - NBE-Therapeutics appoints Dr. Nicole Onetto to its Board of Directors

Nicole Onetto, M.D., medical oncologist with strong track record in the development of targeted therapies in oncology joins NBE-Therapeutics' Board of Directors as independent Board member

Read more

next >